Related references
Note: Only part of the references are listed.Transcriptional master regulator analysis in breast cancer genetic networks
Hugo Tovar et al.
COMPUTATIONAL BIOLOGY AND CHEMISTRY (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Cause and Consequence of Cancer/Testis Antigen Activation in Cancer
Angelique W. Whitehurst
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54 (2014)
TFDP3 was expressed in coordination with E2F1 to inhibit E2F1-mediated apoptosis in prostate cancer
Yueyun Ma et al.
GENE (2014)
Molecular mechanisms of epithelial-mesenchymal transition
Samy Lamouille et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2013)
TGF-beta signaling and epithelial-mesenchymal transition in cancer progression
Yoko Katsuno et al.
CURRENT OPINION IN ONCOLOGY (2013)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2013)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
E2F-1 regulation by an unusual DNA damage-responsive DP partner subunit
L. Ingram et al.
CELL DEATH AND DIFFERENTIATION (2011)
The basics of epithelial-mesenchymal transition
Raghu Kalluri et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis
Jing Yang et al.
DEVELOPMENTAL CELL (2008)
Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition
Anne-Pierre Morel et al.
PLOS ONE (2008)
TFDP3 inhibits E2F1-induced, p53-mediated apoptosis
Chan Tian et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Human TFDP3, a novel DP protein, inhibits DNA binding and transactivation by E2F
Huan Qiao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
A functionally distinct member of the DP family of E2F subunits
A. Milton et al.
ONCOGENE (2006)
The epithelial-mesenchymal transition: new insights in signaling, development, and disease
JM Lee et al.
JOURNAL OF CELL BIOLOGY (2006)
Molecular requirements for epithelial-mesenchymal transition during tumor progression
MA Huber et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
Cancer/testis antigens, gametogenesis and cancer
AJG Simpson et al.
NATURE REVIEWS CANCER (2005)
Epithelial-mesenchymal transition and its implications for fibrosis
R Kalluri et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies
Y Wang et al.
JOURNAL OF IMMUNOLOGY (2002)
Gene expression profiling predicts clinical outcome of breast cancer
LJ van't Veer et al.
NATURE (2002)
Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma
SH Lim et al.
BLOOD (2001)
Share Paper
